首页 正文

A patent review of FGFR4 selective inhibition in cancer (2007-2018)

{{output}}
Introduction: FGFR4 is a tyrosine kinase receptor which, under physiological conditions, is activated upon ligand binding in a highly regulated manner. This triggers downstream signaling related to proliferation and apoptosis res... ...